Exploring Subcutaneous Amivantamab: Patient Preferences and Early Clinical Insights

This discussion examines the development of a subcutaneous formulation of amivantamab for EGFR-mutated non–small cell lung cancer (NSCLC) and its potential impact on patient experience. Panelists will explore why patients may prefer subcutaneous injections over intravenous administration, highlighting benefits such as reduced infusion time, fewer clinic visits, and improved convenience without compromising efficacy. The session will also review early clinical data on the subcutaneous route, including pharmacokinetics, safety, and tolerability, as well as patient-reported outcomes where available. Additionally, practical considerations for implementation in clinical practice, such as training, monitoring, and workflow adjustments, will be discussed. By understanding both patient preferences and emerging evidence, clinicians and pharmacists can better evaluate the potential advantages of subcutaneous amivantamab and its role in personalized, patient-centered care for NSCLC.